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Abstract: 
In an experiment on female Wistar white rats, the osteoprotective effect of atorvastatin, simvastatin and rosuvastatin 
was studied in a model of experimental osteoporosis caused by bilateral ovariectomy. It was found that after 
ovariectomy in female rats develops endothelial dysfunction, including the vessels of the microcirculatory of the 
bone, leading to a deterioration of blood supply to bone tissue and the occurrence of osteoporosis. It was found that 
atorvastatin, simvastatin and rosuvastatin, possessing endothelioprotective activity, prevent deterioration of blood 
supply to bone tissue and thinning of bone trabeculae, thus having anti-osteoporotic activity. 
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INTRODUCTION: 
The reason for the development of osteoporotic bone 
changes is the misalignment of the main processes of 
osteogenesis – bone resorption and remodeling. If 
regional blood supply to the bone is broken, the 
number of osteoblasts decreases and their activity 
slows down, while osteoclasts activate their activity. 
Consequently, the blood supply plays a key role in 
the processes of remodeling and reparative 
regeneration of bone tissue. The structure of the bone 
microvessels themselves differs significantly from 
the vessels of other tissues, they have only the 
endothelial layer, through which all the regulation of 
metabolic processes between osteoclasts, osteoblasts 
and blood take place. Endothelial dysfunction and 
endothelium-associated pathologies are most often 
the main cause of worsening of microcirculatory 
blood flow in bone tissue, which in turn leads to a 
violation of osteogenesis, thereby causing 
osteoporosis [1, 2, 3].  
As is known, in modern pharmacology, there are two 
basic ways of development. The first is the search for 
innovative molecules [4, 5], their thorough in-depth 
study [6, 7], including preclinical [8-12] and clinical 
studies [13], and expensive outcome to the 
pharmaceutical market. The second is the expansion 
of indications for the use of medicines already used 
in medical practice due to the discovery of pleiotropic 
effects [14]. 
Previous studies have demonstrated the positive 
osteoprotective effects of such drugs with 
endotheliotropic properties like enalapril, losartan, 
resveratrol, L-arginine and others. Along with these 
drugs, endothelioprotective properties are also 
possessed by statins, under the influence of which the 
normalization of the course of angiogenesis leading 
to a slowdown in the development of osteoporosis 
[3]. At the same time, in the available literature there 
is no information that anyone should evaluate the 
osteoprotective properties of these drugs, which 
indicates the relevance and determines the purpose of 
this study. 
 
MATERIALS AND METHODS:  
The experiments were carried out on 152 females of 
white Wistar rats weighing 250±50 g. To model 
experimental osteoporosis, rats were anesthetized 
with intraperitoneal administration of a solution of 
chloral hydrate at a dose of 300 mg/kg and bilateral 
ovariectomy was made. The development of 
osteoporosis and anti-osteoporotic action of the 
studied drugs was evaluated after eight weeks (at day 
57) after ovariectomy by evaluating regional 
microcirculation, vascular tests and 
histomorphometric examination. 
The level of microcirculation was evaluated in the 
spongy bone of the proximal metaphysis of the right 
femur. To obtain microcirculation data in the bone, 
Biopac systems equipment was used: polygraph 
MP100-150 with LDF100C laser doppler flowmetry 
(LDF) module and a TSD144 sensor. LDF results 
were recorded by AcqKnowledge ver. 3.8.-4.2., 
microcirculation values were expressed in perfusion 
units (PU). 
Development of hypoestrogeninduced endothelial 
dysfunction was evaluated after measurement of 
intraosseous level of microcirculation, for which was 
carried vascular assays on endothelium-dependent 
vasodilation in response to bolus intravenous 
injection of a solution of acetylcholine in a dose of 40 
μg/kg and endothelium-independent vasodilation in 
response to bolus administration of sodium 
nitroprusside in a dose of 30 μg/kg with subsequent 
calculation of the coefficient of endothelial 
dysfunction (CED), as the ratio of the area of the 
triangle above the microcirculation recovery curve in 
response to the introduction of nitroprusside to the 
area of the triangle above the microcirculation 
recovery curve in response to the introduction of 
acetylcholine. 
To confirm the development of osteoporosis and to 
evaluate the efficacy of the studied drugs, a 
morphological study of the proximal metaphysis of 
the femurs was carried out, for this, slide glasses with 
histological preparations were subjected to light 
microscopy. For carrying out histomorphometry of 
bone tissue, a pre-calibrated program ImageJ ver. 
1.39-1.43 was used, in which the width of bone 
trabeculae was measured and expressed in 
micrometers. 
For the study of osteoprotective action, we selected 
representatives of the group of statins, namely 
atorvastatin, simvastatin and rosuvastatin at a dose of  
0.86 mg/kg. As a comparator, a rather widespread 
drug on the pharmaceutical market and an effective 
drug for prevention and correction of osteoporotic 
disorders was selected – strontium ranelate at a dose 
of 171 mg/kg. The test preparations were 
administered to the animals intragastrically daily 
once a day for eight weeks after ovariectomy as a 
suspension in 1% starch paste. Animals with 
experimental osteoporosis received intragastrically 
1% starch paste as a placebo. The control rats 
included false-operated animals (false ovariectomy 
without ovarian excision), which for eight weeks 
were also given as placebo intragastrically 1% starch 
paste. 
The experimental data obtained in the work were 
subjected to analysis using descriptive statistics 
(Microslot Excel analysis package). The group 
indices determined the mean values (M) and the error 
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of the mean (m). An analysis of statistically 
significant differences in intergroup comparisons was 
carried out using a heteroscedastic t-test (a two-
sample Student t-test with different variances). When 
analyzing a large number of comparisons, Student's 
criterion was used with the Newman-Keils 
correction. 
 
RESULTS: 
On day 57 after bilateral ovariectomy, the level of 
microcirculation in the proximal metaphysis of the 
right femur was evaluated. Results of the study of 
blood supply to bone tissue in rats allowed to identify 
reliably (р<0.001) a lower level of microcirculation 
in the bone tissue of the femur in rats with 
osteoporosis (n=30) – 61.52±3.74 PU, compared to 
control animals (n=42) – 100.51±4.41 PU. 
After measuring the microcirculation in the bone 
tissue of the femur functional vascular tests of 
endothelium-dependent and endothelium-independent 
vasodilation were performed, and the coefficient of 
endothelial dysfunction was calculated for the 
microcirculatory unit of the proximal metaphysis of 
the femur in rats. Thus, in the group of control 
animals, CED =1.30±0.19, in the group of rats with 
experimental osteoporosis CED=2.38±0.23 
(р=0.002), which indicates the development of 
endothelial dysfunction in animals with osteoporosis. 
For further morphological studies, bone biomaterial 
was sampled. Histological sections of the proximal 
parts of the femurs were subjected to microscopy and 
histomorphometry. Osteoporotic changes in the bones 
of the skeleton were histologically confirmed in all 
rats eight weeks after ovariectomy. During the 
microscopy, pathological changes in spongy bone 
tissue of the femur in rats with experimental 
osteoporosis were identified. Thinning of the latticed 
network of bone trabeculae, as well as thinning and 
perforation of bone plates were found. In individual 
histological specimens, micro-fractures of bone 
trabeculae were determined. 
Identified a significant decrease in the average width 
of bone trabeculae in the spongy tissue of the 
proximal metaphysis of the femur. Thus, the average 
width of bone trabeculae in a given location in rats 
with osteoporosis was 61.68±1.24 μm, that is reliably 
(p<0.001) less than that in control animals – 
97.69±1.02 μm. 
Thus, endothelial dysfunction developing in female 
rats due to ovariectomy, including the 
microcirculatory of bone tissue, leads to a marked 
worsening of the regional blood flow, which in turn 
leads to unbalance of bone remodeling processes and 
the appearance of osteoporotic changes in bone 
tissue. 
It was found that the study drugs - the members of 
the statin group, as well as the comparison 
preparation strontium ranelate prevented a decrease 
in the level of regional blood flow in the bone tissue 
of the femur in rats with osteoporosis (Figure 1). 
 
 
Fig 1: Results of the effects of atorvastatin, simvastatin, rosuvastatin and strontium ranelate on the blood 
supply of the proximal metaphysis of the femur 8 weeks after bilateral ovariectomy. * – р<0.05 in comparison 
with animals with osteoporosis. 
 
PU 
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LDF results in the group of rats treated with 
atorvastatin (n=20) significantly (p<0.001) were 
greater than those in the group of rats with 
osteoporosis without treatment, but statistically 
significantly did not differ from the indices in the 
comparison drug group (р=0.432) (n=20).  
Results of LDF in animals treated with simvastatin 
(n=20) also significantly (p<0.001) exceeded the 
LDF values in the group of rats with osteoporosis 
without treatment and did not differ significantly 
(p=0.892) from the results of LDF in animals treated 
with strontium ranelate.  
The LDL results in the group of rats treated with 
rosuvastatin (n=20) were the highest of all studied 
drugs and significantly exceeded both the indices of 
the group of rats with osteoporosis without treatment 
(p<0.001) and those in the comparison drug group 
(p=0.008), and were also comparable to those of 
control animals (р=0.412). 
At the same time, all studied statins possessed 
endothelioprotective activity, significantly preventing 
an increase in the coefficient of endothelial 
dysfunction. In rats treated with atorvastatin 
CED=1.39±0.17 (р=0.015), simvastatin – 
CED=1.61±0.10 (р=0.026), rosuvastatin – 
CED=1.35±0.12 (р=0.017). The preparation of 
comparison of strontium ranelate did not 
authentically possess endothelioprotective activity, 
CED=2.14±0.11 (р=0.532). 
When microscopic sections of the femur bones in rats 
treated with statins found the preservation of the bone 
structure of the proximal metaphysis of the femur. 
When morphometric studies were carried out, it was 
noted the prevention of a decrease in the average 
width of bone trabeculae in the proximal metaphysis 
of the femur in laboratory animals under the 
influence of all studied drugs, as well as the reference 
preparation (Figure 2). Rosuvastatin had the most 
pronounced anti-osteoporotic activity amongst 
statins. 
 
CONCLUSION: 
The endothelial layer of the intraosseous vessels is an 
integral part of the bone, plays a central regulatory 
role, possessing significant metabolic activity, while 
performing various functional actions, which include: 
regulation of leukocyte adhesion, regulation of 
vascular growth, thrombogenicity of vascular wall 
and immune functions. Endothelial cells themselves, 
producing a variety of biologically active substances, 
participate in the regulation of the vascular tone. 
 
 
Fig 2: Results of the effects of atorvastatin, simvastatin, rosuvastatin and strontium ranelate on the average 
width of the bone trabeculae of the proximal metaphysis of the femur 8 weeks after bilateral ovariectomy. * – 
p<0.05 in comparison with animals with osteoporosis. 
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Among a significant number of mediators that are 
produced by the endothelial layer, vasoconstrictors 
are: angiotensin II, endothelin І and vasodilators are: 
nitric oxide (NO), endothelial hyperpolarizing factor, 
prostacyclin. Endothelial dysfunction is an imbalance 
between vasodilating and vasoconstrictor mediators, 
which is characterized by a decrease in vasodilator 
production with activation of vasoconstrictor 
synthesis. The main vasodilator mediator is nitric 
oxide, which as a result of biosynthesis is produced 
from the amino acid L-arginine with the participation 
of the enzyme endothelial nitric oxide synthase (NO-
synthase). The metabolism of L-arginine in cells 
proceeds along two routes: 1st – under the influence 
of arginase L-arginine hydrolyzes into ornithine and 
urea; 2nd – the conversion of L-arginine to nitric 
oxide and citrulline – is catalyzed by NO-synthase 
[15, 16]. In this case, the enzymes arginase and NO-
synthase compete for a common substrate – L-
arginine. In a number of studies, an increase in the 
activity of arginase with the development of 
endothelial dysfunction was revealed. Also, arginase 
inhibits the activity of nitric oxide synthase, 
preventing the production of nitric oxide, and the 
decrease in the effect of arginase leads to an increase 
in the production of nitric oxide, which favorably 
affects the normalization of vascular function.  
The pharmacological effects of statins are based on 
the inhibition of HMG-CoA reductase, the 
mechanism of this effect consists in the agonism to 
the reductase of HMG-CoA, which leads to a 
decrease in the concentration of low-density lipids 
and triglycerides and, as a consequence, to a decrease 
in cholesterol, but the effect of statins on endothelial 
function is more extensive than just lowering 
cholesterol. It has been experimentally proved that 
some drugs are capable of stimulating the 
transcription of the gene NO-synthase in human 
endotheliocytes, which leads to an improvement in 
the expression of NO-synthase, the result is an 
increase in the secretion of nitric oxide in the 
endothelium. Moreover, the use of modern statins, 
including rosuvastatin, positively affects the elastic 
properties of the vessel wall, reduces endothelial 
dysfunction, increasing the functional activity of 
endotheliocytes. Stimulation of NO production in the 
endothelium is characteristic of all statins and does 
not depend on their effect on the synthesis of 
cholesterol. These properties have a positive effect on 
the state of intraosseous microcirculation, thereby 
indirectly improving the trophism of bone tissue, 
including positively affecting osteoregeneration.  
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